Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.44 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL232201 | 0.81 | CYP2A6 (0.60) | CYP2A6MAPTIDO1NPSR1CYP1A2 | |
| SCHEMBL895740 | 0.80 | CYP2A6 (0.64) | CYP2A6MAPTIDO1NPSR1CYP1A2 | |
| SCHEMBL29396424 | 0.80 | CYP2A6 (0.64) | CYP2A6MAPTIDO1NPSR1CYP1A2 | |
| Phosphine SCHEMBL29222824 | 0.79 | CYP2A6 (0.62) | CYP2A6MAPTIDO1NPSR1CYP1A2 | |
| SCHEMBL29222843 | 0.77 | CYP2A6 (0.66) | CYP2A6MAPTIDO1NPSR1CYP1A2 | |
| SCHEMBL1707444 | 0.77 | CYP2A6 (0.60) | CYP2A6MAPTIDO1NPSR1CYP1A2 | |
| SCHEMBL7371792 | 0.76 | CYP2A6 (0.55) | CYP2A6MAPTIDO1NPSR1CYP1A2 | |
| SCHEMBL7271231 | 0.76 | CYP2A6 (0.55) | CYP2A6MAPTIDO1NPSR1CYP1A2 | |
| SCHEMBL4966959 | 0.76 | CYP2A6 (0.55) | CYP2A6MAPTIDO1NPSR1CYP1A2 | |
| SCHEMBL98455 | 0.76 | CYP2A6 (1.00) | CYP2A6MAPTIDO1NPSR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6391917-B1 | ANALGESIC | ZYMOGENETICS, INC. | 2002-05-21 | — | — | US | claimed |
| US-6255351-B1 | TREATMENT OF BONE DISORDERS | ZYMOGENETICS, INC. | 2001-07-03 | — | — | US | claimed |
| US-6221913-B1 | Dialkyl ureas as calcitonin mimetics | ZYMOGENETICS, INC. | 2001-04-24 | — | — | US | claimed |
| EP-0975589-A2 | DIALKYL UREAS AS CALCITONIN MIMETICS | ZymoGenetics, Inc. (US) | 2000-02-02 | — | — | EP | claimed |
| WO-1999037604-A2 | DIALKYL UREAS AS CALCITONIN MIMETICS | ZYMOGENETICS, INC. (US) | 1999-07-29 | — | — | WO | claimed |
| EP-2762150-A1 | Treatment of Diabetes and Metabolic Syndrome | Nordic Bioscience A/S (DK) | 2014-08-06 | — | — | EP | disclosed |
| EP-2405934-B1 | Treatment of diabetes and metabolic syndrome | NORDIC BIOSCIENCE AS (DK) | 2014-03-26 | — | — | EP | disclosed |
| US-20120046224-A1 | TREATMENT OF DIABETES AND METABOLIC SYNDROME | NORDIC BIOSCIENCE A/S (DK) | 2012-02-23 | — | — | US | disclosed |
| EP-2405934-A1 | Treatment of diabetes and metabolic syndrome | Nordic Bioscience A/S (DK) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010103045-A1 | TREATMENT OF DIABETES AND METABOLIC SYNDROME | NORDIC BIOSCIENCE A/S (DK) | 2010-09-16 | — | — | WO | disclosed |
| EP-1505156-B1 | Process for the enantioselective preparation of secondary alcohols by lipase catalysed solvolysis of the corresponding acetoacetic acid ester | CONSORTIUM ELEKTROCHEM IND (DE) | 2005-12-07 | — | — | EP | disclosed |
| US-20050032182-A1 | Process for the enantioselective preparation of secondary alcohols by lipase-catalyzed solvolysis of the corresponding acetoacetic esters | CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH | 2005-02-10 | — | — | US | disclosed |
| EP-1505156-A1 | Process for the enantioselective preparation of secondary alcohols by lipase catalysed solvolysis of the corresponding acetoacetic acid ester | Consortium für elektrochemische Industrie GmbH (DE) | 2005-02-09 | — | — | EP | disclosed |
| US-6391917-B1 | ANALGESIC | ZYMOGENETICS, INC. | 2002-05-21 | — | — | US | disclosed |
| US-6255351-B1 | TREATMENT OF BONE DISORDERS | ZYMOGENETICS, INC. | 2001-07-03 | — | — | US | disclosed |
| US-6221913-B1 | Dialkyl ureas as calcitonin mimetics | ZYMOGENETICS, INC. | 2001-04-24 | — | — | US | disclosed |
| EP-0975589-A2 | DIALKYL UREAS AS CALCITONIN MIMETICS | ZymoGenetics, Inc. (US) | 2000-02-02 | — | — | EP | disclosed |
| WO-1999037604-A2 | DIALKYL UREAS AS CALCITONIN MIMETICS | ZYMOGENETICS, INC. (US) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032182-A1 | Process for the enantioselective preparation of secondary alcohols by lipase-catalyzed solvolysis of the corresponding acetoacetic esters | LIPC, LIPE, LIPA | CYP2A6 296/4885MAPT 4496/4885IDO1 4255/4885 |
| US-20120046224-A1 | TREATMENT OF DIABETES AND METABOLIC SYNDROME | IAPP, GLP1R, CALCA | CYP2A6 3328/4885MAPT 3406/4885IDO1 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.